スズケンJP:9987
時価総額
¥4537.2億
PER
13.8倍
医薬品卸売、ヘルスケア製品開発、地域医療介護支援、スペシャリティ医薬品流通受託、医療関連サービス等を展開する企業。
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| 売上高 | 1,859,917 | 1,894,594 | 1,988,216 | 1,969,689 | 2,228,331 | 2,126,993 | 2,123,997 | 2,132,362 | 2,213,478 | 2,128,218 | 2,232,774 | 2,314,828 | 2,386,493 | 2,399,952 |
| 売上成長率(%) | - | |||||||||||||
| 売上原価 | - | - | - | 1,790,052 | 2,025,741 | 1,933,851 | 1,936,504 | 1,943,050 | 2,019,408 | 1,970,637 | 2,071,780 | 2,135,133 | 2,201,244 | 2,207,720 |
| 売上総利益 | - | - | - | 179,637 | 202,590 | 193,141 | 187,493 | 189,311 | 194,069 | 157,580 | 160,994 | 179,694 | 185,249 | 192,231 |
| 売上総利益率(%) | - | - | - | |||||||||||
| 営業利益率 (%) | - | - | - | |||||||||||
| 営業利益 | - | - | - | 13,240 | 28,244 | 18,712 | 19,735 | 27,228 | 32,571 | 9,156 | 13,777 | 32,605 | 34,875 | 37,125 |
| 営業費用 | - | - | - | 166,390 | 174,219 | 174,513 | 167,775 | 162,066 | 161,552 | 148,683 | 147,216 | 147,089 | 150,373 | 155,106 |
| 経常(税引前)利益 | 23,122 | 27,493 | 35,320 | 30,093 | 45,727 | 27,764 | 29,019 | 36,154 | 41,467 | 18,272 | 23,418 | 36,376 | 38,351 | 38,830 |
| 経常(税引前)利益率(%) | 1.2 | 1.5 | 1.8 | 1.5 | 2.1 | 1.3 | 1.4 | 1.7 | 1.9 | 0.9 | 1 | 1.6 | 1.6 | 1.6 |
| 法人税等合計 | - | - | - | 10,542 | 16,000 | 10,914 | 9,824 | 15,102 | 13,529 | 4,559 | 8,012 | 10,275 | 13,793 | 15,783 |
| 実効税率(%) | - | - | - | |||||||||||
| 純利益 | 1,554 | 9,715 | 14,971 | 18,969 | 29,020 | 21,387 | 18,942 | 30,376 | 28,279 | 5,989 | 13,808 | 14,882 | 21,058 | 25,732 |
| 純利益率(%) | ||||||||||||||
| 一株あたり利益 | 89.3 | 159.19 | 216.3 | 190.82 | 292.13 | 216.92 | 198.21 | 322.73 | 310.26 | 88.52 | 163.19 | 236.47 | 357.88 | 454.58 |
| 希薄化後一株あたり利益 | 89.3 | 159.19 | 216.3 | 190.82 | 292.13 | 216.92 | 198.21 | 322.73 | 310.26 | 88.52 | 163.19 | 236.47 | 357.88 | 454.58 |
| 配当性向(%) | ||||||||||||||
| 一株あたり配当金 | 50 | 50 | 54 | 54 | 69 | 54 | 64 | 69 | 72 | 72 | 72 | 72 | 80 | 100 |
| EBITDA | - | - | - | |||||||||||
| EBITDAマージン(%) | - | - | - |